Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159729 · ClinicalTrials.gov registry record · Phase 2
Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
A Phase 2 study, sponsored by Kythera Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
NCT02159729: Completed Phase 2 study, sponsored by Kythera Biopharmaceuticals.
NCT02159729 is a Phase 2 study that has completed, run by Kythera Biopharmaceuticals. The registered enrollment target is 205 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02159729, a Phase 2 study, has completed, sponsored by Kythera Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
Study Summary
This was a long-term follow-up study of participants who completed Kythera-sponsored trials of ATX-101 (06-03, 07-07, 09-15)
Primary Outcome
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
Interventions
- DRUG Placebo
- DRUG ATX-101 (1 mg/cm^2)
- DRUG ATX-101 (2 mg/cm^2)
- DRUG ATX-101 (4 mg/cm^2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
What the finished NCT02159729 record still lists
NCT02159729 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02159729 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02159729 about?
NCT02159729 is a clinical study titled "Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101". This was a long-term follow-up study of participants who completed Kythera-sponsored trials of ATX-101 (06-03, 07-07, 09-15)
What is the current status of trial NCT02159729?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2009-02. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02159729?
The interventions under investigation include: Placebo (DRUG), ATX-101 (1 mg/cm^2) (DRUG), ATX-101 (2 mg/cm^2) (DRUG), ATX-101 (4 mg/cm^2) (DRUG).
Who is sponsoring clinical trial NCT02159729?
This trial is sponsored by Kythera Biopharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02159729's enrollment target sits among peer trials
205 298th of 2000 higher than 1,702 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05134857 · 205 participants · Phase 2
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
- NCT05181891 · 205 participants · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia